1 CLL histology plays a key role in disease diagnosis, with the peripheral blood smear serving as an important diagnostic tool recommended by the latest International Workshop on CLL (iwCLL) ...

Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the United States. Leukemia is a group of cancers that develop in blood cells. CLL develops in a type of white blood ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

Acalabrutinib–venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL.

The degree of chronic lymphocytic leukemia (CLL) B-cell antigen receptor ... 2 different lots), umbilical cord blood IgM (6 anonymous samples; Tissue Donation Program at the Feinstein Institute ...

3 CLL is a malignancy characterized by the proliferation of mature B lymphocytes in the bone marrow, peripheral blood, lymph nodes, and spleen. Advanced age is a known risk factor for the disease. 2 ...

Peripheral blood smear is easy to perform and relatively cost effective (under US$0.50 per smear [23]) but is laborious, time consuming and requires extensive training and proper quality control ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article ...